TY - JOUR AU - Rusz, Orsolya AU - Pál, Margit AU - Szilágyi, Éva AU - Rovó, László AU - Varga, Zoltán AU - Gyaponyi-Tomisa, Bernadett AU - Fábián, Gabriella AU - Kovács, Levente AU - Nagy, Olga Mária AU - Mózes, Petra AU - Reisz, Zita AU - Tiszlavicz, László AU - Deák, Péter AU - Kahán, Zsuzsanna TI - The Expression of Checkpoint and DNA Repair Genes in Head and Neck Cancer as Possible Predictive Factors JF - PATHOLOGY AND ONCOLOGY RESEARCH J2 - PATHOL ONCOL RES VL - 23 PY - 2017 IS - 2 SP - 253 EP - 264 PG - 12 SN - 1219-4956 DO - 10.1007/s12253-016-0088-z UR - https://m2.mtmt.hu/api/publication/3118609 ID - 3118609 AB - DNA damage response failure may influence the efficacy of DNA-damaging treatments. We determined the expression of 16 genes involved in distinct DNA damage response pathways, in association with the response to standard therapy. Twenty patients with locoregionally advanced, squamous cell head and neck carcinoma were enrolled. The treatment included induction chemotherapy (iChT) with docetaxel, cisplatin and 5-fluorouracil followed by concomitant chemoradiotherapy (ChRT) or radiotherapy (RT) alone. The volumetric metabolic therapeutic response was determined by [18F]FDG-PET/CT. In the tumor and matched normal tissues collected before treatment, the gene expressions were examined via the quantitative real-time polymerase chain reaction (qRT-PCR). The down-regulation of TP53 was apparently associated with a poor response to iChT, its up-regulation with complete regression in 2 cases. 7 cases with down-regulated REV1 expression showed complete regression after ChRT/RT, while 1 case with REV1 overexpression was resistant to RT. The overexpression of WRN was an independent predictor of tumor relapse. Our results suggest that an altered expression of REV1 predicts sensitivity to RT, while WRN overexpression is an unfavorable prognostic factor. LA - English DB - MTMT ER -